- Home
- SITC vs TRDA Comparison
SITC vs TRDA Comparison
Compare SITC & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SITC
- TRDA
- Stock Information
- Founded
- SITC 1965
- TRDA 2016
- Country
- SITC United States
- TRDA United States
- Employees
- SITC N/A
- TRDA N/A
- Industry
- SITC Real Estate Investment Trusts
- TRDA Biotechnology: Pharmaceutical Preparations
- Sector
- SITC Real Estate
- TRDA Health Care
- Exchange
- SITC Nasdaq
- TRDA Nasdaq
- Market Cap
- SITC 603.6M
- TRDA 502.9M
- IPO Year
- SITC 1993
- TRDA 2021
- Fundamental
- Price
- SITC $11.90
- TRDA $8.13
- Analyst Decision
- SITC Hold
- TRDA Strong Buy
- Analyst Count
- SITC 8
- TRDA 3
- Target Price
- SITC $35.25
- TRDA $25.67
- AVG Volume (30 Days)
- SITC 1.2M
- TRDA 168.7K
- Earning Date
- SITC 04-29-2025
- TRDA 05-06-2025
- Dividend Yield
- SITC 4.38%
- TRDA N/A
- EPS Growth
- SITC 101.37
- TRDA N/A
- EPS
- SITC 9.77
- TRDA 1.68
- Revenue
- SITC $278,932,000.00
- TRDA $210,782,000.00
- Revenue This Year
- SITC N/A
- TRDA N/A
- Revenue Next Year
- SITC $13.35
- TRDA N/A
- P/E Ratio
- SITC $1.23
- TRDA $4.84
- Revenue Growth
- SITC N/A
- TRDA 63.38
- 52 Week Low
- SITC $10.46
- TRDA $7.10
- 52 Week High
- SITC $64.44
- TRDA $21.79
- Technical
- Relative Strength Index (RSI)
- SITC 43.59
- TRDA 35.90
- Support Level
- SITC $10.46
- TRDA $7.56
- Resistance Level
- SITC $11.82
- TRDA $8.72
- Average True Range (ATR)
- SITC 0.49
- TRDA 0.66
- MACD
- SITC 0.05
- TRDA 0.07
- Stochastic Oscillator
- SITC 58.74
- TRDA 44.02
About SITC SITE Centers Corp.
SITE Centers Corp is a self-administered and self-managed REIT that operates as a fully integrated real estate company. The company is engaged in the business of owning, leasing, acquiring, redeveloping, developing and managing shopping centers.
About TRDA Entrada Therapeutics Inc.
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.